ArticleBioinformation2026
Evaluation of CD10 expression in prostate adenocarcinoma and its clinic-pathological correlation at tertiary care hospital.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate adenocarcinoma is the second most common cancer in men worldwide and ranks sixth in cancer-related mortality, with more than 95% of cases arising from prostatic acini. CD10, an immunohistochemical marker, has emerged as a potential prognostic indicator, as its high expression is linked to aggressive tumor behavior and early lymph node metastasis, and tumor grading is performed using the WHO Grade Group system based on the Gleason score. Hence, this study included 40 cases of prostate adenocarcinoma diagnosed between January 2023 and December 2024 at the Department of Pathology, MGM Medical College, Indore, involving patients aged 45-95 years with a mean age of 68.5 years. Among the cases evaluated, CD10 expression was negative in 30% (n=12), diffuse in 27.5% (n=11), cytoplasmic in 22.5% (n=9), and membranous in 20% (n=8), and these patterns were correlated with Gleason score. Thus, we show that the pattern of CD10 immunoexpression, particularly diffuse and cytoplasmic positivity, correlates significantly with higher Gleason scores in prostate adenocarcinoma, supporting its incorporation as an adjunct immunohistochemical marker to refine histopathological risk stratification beyond conventional Gleason grading.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.